CO2 fractional laser devices can enable LADD by creating microscopic ablative channels through scar tissue, allowing a topical medication to reach the dermis more effectively than passive application alone. The laser removes narrow columns of tissue and creates micro-thermal zones that breach the stratum corneum and epidermis. A selected agent applied immediately afterward can enter these channels and distribute within targeted dermal scar tissue, where it may complement the laser’s collagen-remodeling effect.
The core principle is sequential treatment: use fractional CO2 laser energy to create controlled microchannels, then apply an appropriate topical therapeutic while those pathways remain accessible. The laser and medication should be treated as a coordinated protocol, not as independent treatments performed at random.
How CO2 Fractional Laser Creates a Delivery Pathway
Microchannels bypass the skin barrier
Fractional CO2 systems produce thousands of microscopic vertical channels within the treated skin. These channels disrupt the stratum corneum, which is normally the main barrier limiting penetration of topical medications.
Because the channels extend into the scar and dermis, they provide a more direct route for selected agents to reach the tissue requiring treatment.
Ablation and coagulation work together
The fractional laser removes narrow columns of scar tissue while producing localized thermal coagulation around each channel. This creates a controlled pattern of injury rather than removing the entire skin surface.
The resulting micro-thermal zones support both drug penetration and the wound-healing response responsible for collagen remodeling and scar contraction.
The channels improve macromolecule delivery
Large-molecule medications and bioactive compounds often penetrate intact skin poorly. LADD reduces this physical limitation by providing micron-scale conduits that can shorten the distance between the topical agent and the target dermal tissue.
This can increase local drug availability compared with topical application on un lasered skin, although the degree of enhancement depends on the agent, formulation, scar characteristics, and laser parameters.
How LADD Fits Into a Scar Management Protocol
1. Select the scar and treatment objective
LADD may be considered for difficult hypertrophic, keloidal, or atrophic scars, depending on the clinical assessment. The treatment objective should be defined first, such as reducing scar thickness, limiting excessive fibroproliferation, improving texture, or addressing contracture.
Scar type, maturity, thickness, pigmentation, vascularity, symptoms, and prior treatment response should guide patient selection.
2. Prepare the treatment area
The scar is evaluated for active infection, inflammation, ulceration, delayed healing, and other factors that could increase procedural risk. A clinician should also review the proposed medication for allergies, contraindications, formulation suitability, and potential systemic absorption.
Laser settings should be individualized to the scar and the patient’s skin characteristics. The appropriate fluence, density, pulse duration, and treatment depth are clinical decisions rather than fixed LADD requirements.
3. Create controlled fractional channels
The CO2 fractional handpiece is passed over the scar to create a controlled matrix of microscopic ablative columns. The treatment should be sufficiently targeted to open delivery pathways while preserving intervening untreated skin to support healing.
For raised scars, the laser may also help soften abnormal tissue and stimulate remodeling. For atrophic scars, the objective may focus more on resurfacing and collagen induction.
4. Apply the selected agent promptly
The medication or bioactive compound is applied immediately after laser treatment, while the microchannels are accessible. The agent should be distributed evenly across the treated scar according to the treating clinician’s protocol.
Examples described in LADD protocols include topical corticosteroids such as triamcinolone acetonide and antimetabolites such as 5-fluorouracil. Other compounds, including PLLA or other bioactive agents, may be considered in specific protocols, but their use requires product-specific evidence and appropriate formulation control.
5. Allow targeted penetration and manage the wound
The medication is allowed to enter the channels for the prescribed contact period. Subsequent wound care should protect the treated area, maintain appropriate moisture, reduce contamination risk, and avoid unapproved products that could irritate the open microchannels.
The patient should receive clear instructions about cleansing, sun protection, expected redness or swelling, and warning signs requiring clinical review.
6. Reassess before repeating treatment
Scar response should be assessed over time using clinically meaningful outcomes such as thickness, pliability, symptoms, pigmentation, texture, and patient-reported improvement. LADD is commonly considered a staged treatment rather than a single procedure for substantial or refractory scars.
Repeat sessions should be based on healing and response, not on a predetermined schedule alone.
Why the Laser and Medication Can Be Synergistic
The laser modifies the scar structure
Fractional CO2 treatment produces controlled injury that can stimulate dermal collagen remodeling and may improve contraction, texture, and firmness. This physical effect is separate from the medication’s pharmacologic action.
The medication acts closer to the target tissue
When a topical drug enters laser-created channels, it can reach the dermal component of the scar more directly. For hyperproliferative scars, agents such as corticosteroids or 5-fluorouracil may be selected to help suppress excessive scar activity.
The intended benefit is greater local exposure with less dependence on passive diffusion through intact skin.
The combined approach targets multiple mechanisms
The laser can improve scar architecture and create the delivery route, while the medication modifies cellular behavior within the scar. This combination is particularly relevant when a scar is resistant to topical treatment alone or when deeper dermal access is needed.
The approach should still be viewed as an adjunct to a broader scar management plan, which may include pressure therapy, silicone, injections, surgery, or other interventions when clinically appropriate.
Understanding the Trade-offs
Increased penetration also increases risk
Bypassing the skin barrier can increase local drug exposure, but it can also increase irritation, inflammation, allergic reactions, pigmentary change, and—depending on the agent—systemic absorption. A medication suitable for intact skin is not automatically suitable for application to laser-created channels.
Only agents with an appropriate clinical rationale, formulation, and safety profile should be used.
Laser parameters affect both efficacy and safety
Higher treatment density or energy may create deeper or more numerous channels, but it can also increase downtime and the risk of prolonged erythema, infection, post-inflammatory hyperpigmentation, hypopigmentation, delayed healing, or worsening scarring.
Treatment intensity should therefore be individualized, especially in patients with darker skin types, a history of abnormal scarring, or impaired wound healing.
Evidence is not uniform for every agent
The principle of channel-assisted delivery is well established, but clinical evidence varies by medication, scar type, formulation, laser platform, and treatment protocol. Evidence for one agent or indication should not be generalized automatically to another.
In particular, products such as PLLA require careful consideration of formulation, sterility, regulatory status, and tissue compatibility before use in a post-ablative setting.
Keloids require additional caution
Keloids can extend beyond the original wound and may recur after injury. Fractional CO2 LADD may be incorporated into specialist management, but it should not be assumed to replace established recurrence-prevention strategies or careful long-term follow-up.
LADD is not simply “laser plus cream”
The procedure depends on coordinated decisions about scar selection, laser depth and density, drug choice, timing, wound care, and monitoring. Applying an unsuitable topical product to freshly ablated skin can create harm without providing a reliable therapeutic benefit.
Making the Right Choice for Your Goal
A practical protocol should match the delivery strategy to the scar biology and the medication’s safety requirements.
- If your primary focus is reducing hypertrophic or keloidal scar activity: Consider specialist-directed LADD using an appropriate anti-proliferative or corticosteroid-based agent, with recurrence prevention and follow-up included in the protocol.
- If your primary focus is improving atrophic scar texture: Use fractional CO2 treatment primarily for controlled resurfacing and collagen remodeling, adding a topical agent only when its formulation and evidence support post-laser delivery.
- If your primary focus is maximizing local drug exposure: Apply the selected medication promptly after channel creation and use a standardized protocol for dose, contact time, wound care, and adverse-event monitoring.
- If your primary focus is patient safety: Individualize laser parameters, screen for infection and healing risks, avoid unvalidated products, and monitor closely for pigmentary change, infection, delayed healing, and excessive inflammation.
Used with appropriate patient selection and medication controls, fractional CO2 LADD turns controlled microchannel creation into a targeted strategy for combining scar remodeling with localized dermal therapy.
Summary Table:
| Aspect | Key Points |
|---|---|
| Mechanism | Creates microscopic channels to bypass skin barrier, enhancing drug penetration |
| Procedure | Sequential treatment: laser ablation followed by immediate topical application |
| Suitable Scars | Hypertrophic, keloidal, atrophic scars requiring targeted therapy |
| Benefits | Improved drug delivery, synergistic effects on collagen remodeling and scar activity |
| Risks | Increased irritation, pigmentary changes, need for careful patient selection |
| Evidence | Varies by agent; clinical judgment and protocol adherence essential |
Elevate Your Practice with BELIS LADD Solutions
At BELIS, we specialize in professional-grade medical aesthetic equipment designed for clinics and premium salons. Our advanced CO2 fractional laser systems are ideal for enabling laser-assisted drug delivery (LADD) in scar management protocols. By integrating our precise laser technology with your expertise, you can offer cutting-edge treatments that enhance patient outcomes and expand your service portfolio.
Contact us today to learn how our devices can support your clinical goals and drive practice growth. Get in touch with our team to discuss partnership opportunities or schedule a demo.
Related Products
- Fractional CO2 Laser Machine for Skin Treatment
- Fractional CO2 Laser Machine for Skin Treatment
- Cryolipolysis Fat Freezing Cavitation Lipo Laser Machine
- Ultrasonic Cavitation Machine Lipo Laser Device
- RF Microneedling Machine Micro Needle Radio Frequency Machine
People Also Ask
- What is the technical principle behind CO2 Laser Fractional micro-perforations? Master Scar Revision Mechanics
- Why are professional laser systems, such as CO2 fractional or Erbium lasers, more effective for deep wrinkle reduction and dermal remodeling than topical anti-aging ingredients like retinoids, vitamin C, or peptides? Discover the targeted power of fractional lasers.
- What is the rationale for a double-pass technique with fractional CO2 lasers? Maximize Deep Collagen Remodeling
- What role does fractional CO2 laser equipment play in the treatment of SUI? Non-Surgical Stress Urinary Incontinence Care
- What is the purpose of manually extracting large cysts before CO2 fractional laser? Optimize Eyelid Milia En Plaque Care
